Previous unpublished studies by others on file at the manufacturer claimed that treatment with Acclydine would be more effective in CFS patients with a higher IGFBP3/IGF1 ratio. This evidence concerns the gene IGF1 and myalgic encephalomeyelitis/chronic fatigue syndrome.